Introduction
Chromosomal translocations targeting JAK2 are rare but recurrent abnormalities seen in myeloproliferative neoplasms (MPN), acute myeloid leukemia, acute lymphoblastic leukemia and lymphoma. [1] [2] [3] [4] [5] [6] [7] 
Design and Methods
To assess response to ruxolitinib in cell line models, Ba/F3 cells were transfected with pcDNA3. (5)t(3;5)(q26;q14), der(7)t(7;9)(q21;p24),r(9)(p13q34),der(12)t(12;18)(p12;p11),r(18)(p11q21) [19) . FISH and comparative genomic hybridization (CGH) analysis revealed overamplification of JAK2 and genetic analysis showed the patient to be negative for JAK2 V617F.
Primary cells were set up at 2x10 5 /ml in methylcellulose with cytokines without erythropoietin (Stem Cell Technologies, Vancouver, BC) in triplicate for each inhibitor dose.
Colonies greater than 50 cells were counted on day 7 and colonies greater than 100 cells were counted on day 14. An index of growth response was calculated as described previously.
11
FISH was used to assess any differential effect of ruxolitinib upon colonies with or without rearranged or amplified JAK2. Colonies were plucked into 3:1 methanol/acetic acid, stored at -20°C until required then pipetted onto slides. Split-apart FISH with differentially labeled bacmid probes RP11-3H3 (5´ JAK2) and RP11-28A9 (3´ JAK2) was performed according to established techniques 12 with the addition of a 70% acetic acid wash immediately after slide making and a refix in 1% paraformaldehyde in PBS for 10 minutes before hybridization.
Results and Discussion
The IL3-dependent Ba/F3 cell line can be transformed to IL3 independence by expression of activated oncogenes such as ETV6-JAK2 and thereby provides a model system for assessing tyrosine kinase inhibitors. 1 In initial experiments Ba/F3-ETV6-JAK2 clones and untransformed Ba/F3 cells (grown with IL3) showed similar responses to ruxolitinib consistent with the requirement of JAK2 for IL3 signalling. 13 We therefore used the Our data together with previous data on ruxolitinib pharmacology 15 (25 mg dose gives a C max of 934 nM) therefore suggests that effective inhibition of JAK2 fusion proteins would be readily obtainable in vivo.
Ruxolitinib was then assessed in in vitro assays using primary material from two patients with JAK2 rearrangements, one patient with JAK2 amplification, seven healthy controls and three CML controls. JAK2 amplification is very rare in haematological malignancies and has not previously been described in myelodysplastic syndrome. CGH and FISH showed amplification of a region on chromosome 9 containing JAK2 (Figure 2A, B) . The total number of copies of JAK2 was estimated at 6-7 per cell suggesting increased JAK2 signalling and a potential response to ruxolitinib. Cells from all three patients were grown for two weeks in methylcellulose in the presence of ruxolitinib. An overall reduction in colony growth was seen in patients compared with healthy controls (t-test, p<0.05) and CML controls ( Figure 3A ) which was progressive with increasing ruxolitinib concentration ( Figure   3B ). Colonies were plucked into fixative followed by FISH analysis using split-apart JAK2
probes to assess the proportions of JAK2-rearrangement positive and negative cells at each ruxolitinib concentration and this data was combined with colony counts to show the relative dynamics of the JAK2-rearrangement positive and negative fractions (Figure 3C and D; calculations are provided in Supplementary Table 2 ). In both cases 1 and 2 the reduction in JAK2-rearrangement positive cells occurs at lower ruxolitinib concentrations and is greater than that seen in JAK2-rearrangement negative cells at all concentrations. Both patients with JAK2 rearrangements showed an overall reduction in JAK2 rearranged colonies (chi-squared test; case 1, p<0.02; case 2, p<0.05). In case 1, complete eradication of PCM1-JAK2 positive colonies at 500 nM ruxolitinib was seen. For case 3, only JAK2-amplified colonies were seen (65 and 11 colonies analysed by FISH from 100 nM and 500 nM ruxolitinib treated cultures respectively) suggesting that the level of cells negative for the JAK2-amplification may be too low to allow detection of a differential effect using this assay.
In summary we have shown by in vitro assays using both cell line models and primary patient material that ruxolitinib has significant activity against JAK2 activated by gene rearrangement and present evidence for potential activity against cells with JAK2 amplification. Since aberrant activation of JAK2 has also been demonstrated in lymphoid disorders e.g. by JAK2 rearrangement or SOCS1 mutation in lymphoma 7, 16 and CRLF2, IL7R
and JAK family mutations in acute lymphoblastic leukemia, 17, 18 it is possible that treatment with ruxolitinib will have wider potential applicability in addition to treatment of patients with JAK2 rearrangement-positive MPN described here.
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